Roni Appel - Ayala Pharmaceuticals Independent Director
| ADXSDelisted Stock | USD 0.62 0.03 4.62% |
Director
Mr. Roni A. Appel is Independent Director of the Company. He was our President and Chief Executive Officer from January 1, 2006 and Secretary and Chief Financial Officer from November 2004, until he resigned as our Chief Financial Officer on September 7, 2006 and as our President, Chief Executive Officer and Secretary on December 15, 2006. From December 15, 2006 to December 2007, Mr. Appel served as a consultant to us since 2006.
| Age | 51 |
| Tenure | 18 years |
| Professional Marks | MBA |
| Phone | 609 452-9813 |
| Web | www.ayalapharma.com |
Ayala Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (24.13) % which means that it has lost $24.13 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (41.98) %, meaning that it created substantial loss on money invested by shareholders. Ayala Pharmaceuticals' management efficiency ratios could be used to measure how well Ayala Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 19 K in liabilities. Ayala Pharmaceuticals has a current ratio of 15.33, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Ayala Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Ayala Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ayala Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ayala to invest in growth at high rates of return. When we think about Ayala Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Valier Boivin | Acasti Pharma | N/A | |
| Jean Belanger | Acasti Pharma | N/A | |
| Reed Tuckson | Acasti Pharma | 63 | |
| Katherine Crewe | Acasti Pharma | N/A | |
| Carolyn Egbert | Aeterna Zentaris | N/A | |
| Pierre Fitzgibbon | Acasti Pharma | 60 | |
| Michael Cardiff | Aeterna Zentaris | N/A | |
| Pierre Lapalme | Aeterna Zentaris | 75 | |
| Richard Schottenfeld | Acasti Pharma | N/A | |
| JeanMarie Canan | Acasti Pharma | 57 | |
| JeanDaniel Belanger | Acasti Pharma | N/A | |
| Juergen Ernst | Aeterna Zentaris | 77 | |
| JeanClaude Debard | Acasti Pharma | N/A | |
| Jose Dorais | Aeterna Zentaris | N/A | |
| Kenneth Newport | Aeterna Zentaris | 48 | |
| Gerard Limoges | Aeterna Zentaris | 74 | |
| Adrian Montgomery | Acasti Pharma | N/A | |
| Marcel Aubut | Aeterna Zentaris | N/A | |
| Donald Olds | Acasti Pharma | 57 | |
Management Performance
| Return On Equity | -41.98 | ||||
| Return On Asset | -24.13 |
Ayala Pharmaceuticals Leadership Team
Elected by the shareholders, the Ayala Pharmaceuticals' board of directors comprises two types of representatives: Ayala Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ayala. The board's role is to monitor Ayala Pharmaceuticals' management team and ensure that shareholders' interests are well served. Ayala Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ayala Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Sidransky, Independent Director | ||
| Mayo Pujols, VP of Manufacturing | ||
| Anthony Lombardo, Interim CEO | ||
| Richard Schwalm, Independent Director | ||
| Kenneth Berlin, President CEO, Director | ||
| Roni Appel, Independent Director | ||
| Richard Berman, Independent Director | ||
| Samir Khleif, Director | ||
| Ranya Dajani, Vice President Business Development | ||
| James Patton, Non-Executive Independent Chairman of the Board | ||
| Sara Bonstein, CFO and Sr. VP | ||
| Thomas McKearn, Independent Director | ||
| Tom Ridge, Director | ||
| Christopher Duke, COO, Senior Vice President | ||
| Robert Petit, Chief Scientific Officer and Executive VP | ||
| Molly Henderson, CFO, Executive Vice President | ||
| Daniel OConnor, President CEO, Director | ||
| David Mauro, Executive Vice President Chief Medical Officer | ||
| Gregory Mayes, COO, Executive Vice President |
Ayala Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Ayala Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -41.98 | ||||
| Return On Asset | -24.13 | ||||
| Current Valuation | (25.1 M) | ||||
| Shares Outstanding | 145.64 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Number Of Shares Shorted | 39.89 K | ||||
| Price To Earning | (1.62) X | ||||
| Price To Book | 5.25 X | ||||
| Price To Sales | 990.34 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ayala Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ayala Pharmaceuticals' short interest history, or implied volatility extrapolated from Ayala Pharmaceuticals options trading.
Pair Trading with Ayala Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ayala Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ayala Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Ayala Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ayala Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ayala Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ayala Pharmaceuticals to buy it.
The correlation of Ayala Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ayala Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ayala Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ayala Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Ayala OTC Stock
If you are still planning to invest in Ayala Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ayala Pharmaceuticals' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |